No Data
Special treat Burin (002424.SZ): The small-scale testing of the new process route for the Tefentai project has successfully concluded and is currently undergoing pilot verification.
Gelonghui, December 3rd, ST BaiLing (002424.SZ) stated on the investor interaction platform that the trial of the new process route for the Teofinde project has successfully concluded, and is currently undergoing pilot verification. If successful, samples can be produced according to the new process to conduct clinical trials for drug interactions.
Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) Held Back By Insufficient Growth Even After Shares Climb 26%
Bailing Pharma Gets Clinical Trial Approval for Diabetic Retinopathy Traditional Chinese Tablets; Shares Rise 5%
ST Bailing (002424.SZ): The application for clinical trial of Tanging Tongluo片 by its wholly-owned subsidiary has been approved.
On November 12, GeLongHui reported that on November 12, 2024, the company's wholly-owned subsidiary, BeLingYuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as 'BeLingYuxiu'), received the 'Drug Clinical Trial Approval Notification Letter' issued by the National Medical Products Administration (NMPA) (Notification No.: 2024LP02560). The clinical trial application for Tongning Tongluo tablets submitted by BeLingYuxiu has been approved, allowing the product to conduct Phase III clinical trials for diabetic retinopathy.
ST Bai Ling (002424.SZ): Currently, there are no drugs specifically treating dengue fever.
Gelonghui November 11th | ST Baoling (002424.SZ) stated on the investor interaction platform that the company currently does not have a direct treatment for dengue fever, but recommends that you consult professional medical institutions or health departments for the latest information and advice on dengue fever treatment and prevention.
November 11th A-share investment lightning rod︱Shanghai Prosolar Resources Development: the actual controller Yu Zengyun is under investigation for suspected illegal fundraising.
Huibo New Materials' shareholder, Cigna New Materials Industry Investment Fund, and its concerted action parties plan to collectively reduce their shareholding by no more than 3%; Jiangsu Lihua Animal Husbandry, a shareholder of Lihua Stock, and Cangshi Investment plan to collectively reduce their shareholding by no more than 3%; special treat Bailin is under investigation by the CSRC for suspected violations of information disclosure laws and regulations; Shanghai Prosolar Resources Development's actual controller Yu Zengyun is under investigation for suspected fundraising fraud.
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s (SZSE:002424) Earnings Haven't Escaped The Attention Of Investors
